Fubotv earnings beat by $0.10, revenue topped estimates
Smith+Nephew PLC (LSE:SN, NYSE: SNN), a global medical technology company, announced today the appointment of David King as an independent Non-Executive Director, effective from July 1, 2025. David King will also serve on the Compliance & Culture and the Remuneration Committees.
David King’s extensive background includes his current role as CEO, executive director, and chair of Fortis (NYSE:FTS) Life Sciences. He has held significant positions on the boards of various healthcare companies, such as ZimVie, VaxCare, and Privia Health, among others. His previous experience includes serving as executive chair and CEO for Laboratory Corporation of America (NYSE:LH) (LabCorp) from 2007 to 2020 and being a partner at Hogan & Hartson LLP.
Rupert Soames, Chair of Smith+Nephew, expressed enthusiasm for King’s arrival, highlighting his vast experience in healthcare and life sciences sectors and his contributions to business growth in the US and globally.
Smith+Nephew, founded in 1856 in Hull, UK, specializes in the repair, regeneration, and replacement of soft and hard tissue. With a mission termed ’Life Unlimited,’ the company’s 17,000 employees strive to improve patients’ lives through product quality and technological innovation. In 2024, Smith+Nephew reported annual sales of $5.8 billion and is listed on the FTSE100.
The company’s SEC filing indicated that there are no disclosure obligations under UK Listing Authority’s Listing Rules in respect of the new appointment.
This news is based on a press release statement from Smith+Nephew and the SEC filing made on June 13, 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.